Related Experiment Video
Updated: Jun 6, 2026

14:14
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
Published on: August 12, 2018
Bilateral pallidal deep brain stimulation in primary Meige syndrome
Wataru Sako1, Ryoma Morigaki, Yoshifumi Mizobuchi
1Parkinson's Disease and Dystonia Research Center, Tokushima University Hospital, Tokushima 770-8503, Japan.
Parkinsonism & Related Disorders
|December 15, 2010
Summary
Deep brain stimulation (DBS) of the globus pallidus internus (GPi) significantly improved Meige syndrome symptoms. This treatment offers long-term relief for disabling craniofacial and cervical dystonias.
Area of Science:
- Neurology
- Neurosurgery
Background:
- Meige syndrome is an idiopathic movement disorder causing craniofacial and cervical dystonias.
- Deep brain stimulation (DBS) of the globus pallidus internus (GPi) is a recognized treatment for generalized dystonia.
- Limited data exists on GPi-DBS efficacy specifically for Meige syndrome.
Purpose of the Study:
- To evaluate the long-term effectiveness of bilateral GPi-DBS in patients with primary Meige syndrome.
- To assess the impact of GPi-DBS on dystonia severity and disability in Meige syndrome.
Main Methods:
- A cohort of 5 patients with disabling Meige syndrome underwent bilateral GPi-DBS.
- Patients were assessed pre-operatively and at long-term follow-up using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS).
- BFMDRS movement and disability scores were analyzed to quantify treatment outcomes.
Main Results:
- Bilateral GPi-DBS demonstrated sustained and significant improvement in dystonia symptoms.
- Mean BFMDRS movement scores improved by 84% (range, 75-94%).
- Mean BFMDRS disability scores improved by 89% (range, 80-100%) at the last follow-up.
Conclusions:
- Bilateral pallidal stimulation is an effective therapeutic option for Meige syndrome.
- GPi-DBS provides long-term relief from disabling dystonia symptoms in Meige syndrome patients.
- This study supports GPi-DBS as a beneficial treatment for Meige syndrome.

